Evidence map›Paper›PMID 23145203›Full record

ArticlePLoS neglected tropical diseases2012

Mechanistic and single-dose in vivo therapeutic studies of Cry5B anthelmintic action against hookworms.

Yan Hu, Bin Zhan, Brian Keegan, Ying Y Yiu, Melanie M Miller, Kathryn Jones, Raffi V Aroian

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. An inactivated bacterium (paraprobiotic) expressingOne health (Amsterdam, Netherlands) · 2021
    Article
  14. Article
  15. Article
  16. A new paraprobiotic-based treatment for control of Haemonchus contortus in sheep.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  17. Article
  18. The American journal of tropical medicine and hygiene · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yan HuSection of Cell and Developmental Biology, University of California San Diego, La Jolla, California, United States of America. bzhan@bcm.edu
Bin Zhan
Brian Keegan
Ying Y Yiu
Melanie M Miller
Kathryn Jones
Raffi V Aroian
University of California, San Diego · USBaylor College of Medicine · US

Funding

Function/optimization of a nematicidal Cry toxin arsenalR01AI056189 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAFFI V AROIAN · 2005 to 2026
$11.0M
NIAID NIH HHS 2R01AI056189NIAID NIH HHS R01 AI056189
6 · The paper itself

Abstract

backgroundHookworm infections are one of the most important parasitic infections of humans worldwide, considered by some second only to malaria in associated disease burden. Single-dose mass drug administration for soil-transmitted helminths, including hookworms, relies primarily on albendazole, which has variable efficacy. New and better hookworm therapies are urgently needed. Bacillus thuringiensis crystal protein Cry5B has potential as a novel anthelmintic and has been extensively studied in the roundworm Caenorhabditis elegans. Here, we ask whether single-dose Cry5B can provide therapy against a hookworm infection and whether C. elegans mechanism-of-action studies are relevant to hookworms. METHODOLOGY/PRINCIPAL

findingsTo test whether the C. elegans invertebrate-specific glycolipid receptor for Cry5B is relevant in hookworms, we fed Ancylostoma ceylanicum hookworm adults Cry5B with and without galactose, an inhibitor of Cry5B-C. elegans glycolipid interactions. As with C. elegans, galactose inhibits Cry5B toxicity in A. ceylanicum. Furthermore, p38 mitogen-activated protein kinase (MAPK), which controls one of the most important Cry5B signal transduction responses in C. elegans, is functionally operational in hookworms. A. ceylanicum hookworms treated with Cry5B up-regulate p38 MAPK and knock down of p38 MAPK activity in hookworms results in hypersensitivity of A. ceylanicum adults to Cry5B attack. Single-dose Cry5B is able to reduce by >90% A. ceylanicum hookworm burdens from infected hamsters, in the process eliminating hookworm egg shedding in feces and protecting infected hamsters from blood loss. Anthelmintic activity is increased about 3-fold, eliminating >97% of the parasites with a single 3 mg dose (∼30 mg/kg), by incorporating a simple formulation to help prevent digestion in the acidic stomach of the host mammal. CONCLUSIONS/SIGNIFICANCE: These studies advance the development of Cry5B protein as a potent, safe single-dose anthelmintic for hookworm therapy and make available the information of how Cry5B functions in C. elegans in order to study and improve Cry5B function against hookworms.

Indexed as

AncylostomaAncylostomiasisAnimalsAnthelminticsBacillus thuringiensis ToxinsBacterial ProteinsCricetinaeDisease Models, AnimalEndotoxinsFecesFemaleHemolysin ProteinsMaleMesocricetusParasite Egg CountTreatment OutcomeAnthelminticsBacillus thuringiensis ToxinsBacterial ProteinsEndotoxinsHemolysin Proteinsinsecticidal crystal protein, Bacillus Thuringiensis

Identifiers

PMID23145203
PMCPMC3493396
OpenAlexW2031971291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.